# Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer

> **NCT04158362** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **UNICANCER** · enrollment: 180 (actual)

## Conditions studied

- Cancer Metastatic

## Interventions

- **DRUG:** Paclitaxel injection
- **DRUG:** Capecitabine tablets
- **DRUG:** Letrozole 2.5mg
- **DRUG:** Anastrozole 1mg
- **DRUG:** Fulvestrant Prefilled Syringe
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT04158362
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-11
- **Primary completion:** 2025-04-30
- **Final completion:** 2028-06
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04158362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04158362, "Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04158362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*